Fund Holdings — Versant Venture Management, LLC

Total Portfolio Value
$141.41M
Total Bought
$27.50M
Total Sold
$16.40M
Net Transaction
+$11.10M
Filing Period:
Securities
▲▼
SharesValue ($K)
Q4 2025
▲▼
Q1 2026
▲▼
Change
▲▼
Q4 2025
▲▼
Q1 2026
▲▼
Weight (%)
▲▼
Change
▲▼
Century Therapeutics, Inc.(IPSC)012,166,109+12,166,109027,49519.44%+27,495
Contineum Therapeutics, Inc.(CTNM)542,628542,62806,2027,0875.01%+884
Skye Bioscience, Inc.(SKYE)2,007,7042,007,70401,5051,2340.87%-271
Tempest Therapeutics, Inc.(TPST)269,772269,77207744420.31%-332
CRISPR Therapeutics AG(CRSP)148,831148,83107,8057,0805.01%-725
Jade Biosciences, Inc.1,525,8201,525,820023,54321,43815.16%-2,106
Monte Rosa Therapeutics, Inc.(GLUE)4,382,6873,180,780-1,201,90768,72152,32437.00%-16,397
Lenz Therapeutics, Inc.(LENZ)2,656,8882,656,888042,51024,31117.19%-18,200
Page 1 of 1
Versant Venture Management, LLC — 13F Holdings — Q1 2026 | TickerTrail